% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • rojospan rojospan Dec 29, 2011 7:06 PM Flag

    VRTX starts phase II b of VX 765


    Trial is going to recruit 400 patient this time with different dosage for treatment resistant partial epilepsy. Previous trials used 900 mg dose tid in small sample of 60 patients in phase II a. Study will be conducted for approximately 2 years or 25 months to see the reduction in seizure frequencies.

    VX 765 is a caspase inhibitor which blocks IL-1b, thus decrease inflammation in the brain.

    It would have been nice if they do a pilot study in post cardiac arrest patients to see if this drug, in addition to medically induced hypothermia, can decrease cerebral edema and thus anoxic brain injury. This is an unmet medical need that can bring bigger dollars than Hep C and CF.

    VX 809 and VX 770 trial has 160 patients and if it is positive, VRTX may be able to file for NDA based on II b trial. This can be a good surprise to analysts.

    Polymerase N5B target remains tricky and this probably will need 2 or more drugs to block the virus at this target site. I think non-nucleoside drugs will be safer than nucleoside inhibitors in long run and I am hoping to see a viable all oral result from Zenith trial.

    Good luck and Happy new year to all longs. Drugs brings good business when they are most effective in their class.

    VRTX need to accelerate VX 509 development.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
88.84-0.28(-0.31%)Sep 28 4:00 PMEDT